Trial Profile

An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary)
Indications Follicular lymphoma
Focus Therapeutic Use
Acronyms DAWN
Sponsors Janssen Research & Development

Most Recent Events

04 Dec 2018 Results of the biomarker analysis assessing whether somatic mutations could be used to identify FL patients who responded to ibrutinib, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
31 May 2018 Primary endpoint (Overall response rate) has not been met, according to results published in the Journal of Clinical Oncology.
31 May 2018 Results (n=110) published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com